
|Articles|November 14, 2007
Approval for pain reliever for osteoarthritic knees to be delayed
Genzyme has to provide FDA with more data on Synvisc-One before the pain-relieving treatment for osteoarthritis can be approved.
Advertisement
Those who were waiting for the approval of Synvisc-One will have to wait a little longer. Genzyme Corp., which is applying for approval of the next generation of Synvisc (hylan G-F 20),
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Heat and Older Adults: What Pharmacists Need to Know
5





























































